Previous Article | Next Article ![]()
Journal of Virology, October 2001, p. 9713-9722, Vol. 75, No. 20
Departments of
Pediatrics,1 Molecular Virology and
Microbiology,2 and
Medicine-Gastroenterology,4 Baylor
College of Medicine, Houston, Texas 77030, and Department
of Microbiology and Immunology, Tulane University Medical Center,
New Orleans, Louisiana 701123
Received 26 January 2001/Accepted 25 July 2001
Recombinant Norwalk virus-like particles (rNV VLPs) were
administered to BALB/c mice by the intranasal (i.n.) route to evaluate the induction of mucosal antibody responses. The results were compared
to systemic and mucosal responses observed in new and previous studies
(J. M. Ball, M. E. Hardy, R. L. Atmar, M. E. Connor, and M. K. Estes, J. Virol. 72:1345-1353, 1998) after oral administration of rNV VLPs. Immunizations were given in the presence or
absence of a mucosal adjuvant, mutant Escherichia coli
heat-labile toxin LT(R192G). rNV-specific immunoglobulin G (IgG) and
fecal IgA were evaluated by enzyme-linked immunosorbent assay. The i.n. delivery of rNV VLPs was more effective than the oral route at inducing
serum IgG and fecal IgA responses to low doses of rNV particles.
Vaginal responses of female mice given VLPs by the i.n. and oral routes
were also examined. All mice that received two immunizations with low
doses i.n. (10 or 25 µg) of rNV VLPs and the majority of mice that
received two high doses orally (200 µg) in the absence of adjuvant
had rNV-specific serum IgG, fecal, and vaginal responses. Additional
experiments evaluated whether rNV VLPs can function as a mucosal
adjuvant by evaluating the immune responses to two soluble proteins,
keyhole limpet hemocyanin and chicken egg albumin. Under the conditions
tested, rNV VLPs did not enhance the serum IgG or fecal IgA response to
these soluble proteins when coadministered by the i.n. or oral route.
Low doses of nonreplicating rNV VLPs are immunogenic when administered
i.n. in the absence of adjuvant, and addition of adjuvant enhanced the
magnitude and duration of these responses. Recombinant NV VLPs
represent a candidate mucosal vaccine for NV infections in humans.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9713-9722.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Recombinant Norwalk Virus-Like Particles
Administered Intranasally to Mice Induce Systemic and Mucosal
(Fecal and Vaginal) Immune Responses


*
Corresponding author. Mailing address: Division of
Molecular Virology and Microbiology, Baylor College of Medicine, One
Baylor Plaza, Houston, TX 77030. Phone: (713) 798-3585. Fax: (713)
798-3586. E-mail: mestes{at}bcm.tmc.edu.
Present address: Children's Gastroenterology of South Florida,
West Palm Beach, FL 33470.
Present address: Department of Veterinary Pathobiology, Texas
A & M University, College Station, TX 77843.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»